At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Aflibercept +1 moredrug
Likely dose
Aflibercept 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery
In Brief
A Phase 2 clinical trial evaluating Aflibercept and Sham for Diabetic Retinopathy. Completed, enrolled 30 participants across 1 site.
Detailed Summary
To determine the safety and efficacy of intravitreal Aflibercept (Eylea) injection in patients with diabetic retinopathy in the prevention of macular edema following cataract surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Retinopathy
CountriesUnited States
CollaboratorsRegeneron Pharmaceuticals
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedNov 2013
Enrollment StartDec 2013
Primary CompletionApr 2018
Study CompletionJan 2020
TodayJul 2026
First PostedNov 20, 2013
Enrollment StartDec 1, 2013
Primary CompletionApr 25, 2018
Study CompletionJan 14, 2020
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 12.6 years ago
Interventions
Afliberceptdrug
Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.
Shamdrug
Sham injection. No actual injection. No medication is used.